Coherus Biosciences (CHRS) PT Lowered to $25 at JPMorgan
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.42 +3.65%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
JPMorgan lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $32.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
- The Campbell's Co. (CPB) PT Raised to $19 at UBS, Sell Rating Maintained
- Asana (ASAN) PT Raised to $9 at DA Davidson, Neutral Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
